Oncologists are slightly less satisfied with their specialty than they were a few years ago, according to the fifth consecutive annual Medscape report.
Times are changing for oncologists, as they are in medicine in general. And oncologists are slightly less satisfied with their specialty than they were a few years ago, according to the fifth consecutive annual Medscape report.
The latest figures, covering 2014 earnings, were compiled from an extensive online survey of 19,916 physicians. Around 2% (n = 398) of the respondents were oncologists. Their responses are summarized in the Oncologist Compensation Report 2015.
Overall, oncologists were well compensated; average yearly earnings were $302,000, ranking them slightly above the median for all specialties. As in previous reports, orthopedists top the income list ($421,000), followed by cardiologists ($376,000) and gastroenterologists ($370,000). At the bottom of the income list were pediatricians ($189,000), family medicine physicians ($195,000), and those in internal medicine and diabetes/endocrinology ($196,000).
Link to the article on Medscape:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More